Search results for "Alcohol"

showing 10 items of 1798 documents

GDF11 induces mild hepatic fibrosis independent of metabolic health

2020

BACKGROUND & AIMS: Growth Differentiation Factor 11 (GDF11) is an anti-aging factor, yet its role in liver diseases is not established. We evaluated the role of GDF11 in healthy conditions and in the transition from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH). RESULTS: GDF11 mRNA levels positively correlated with NAFLD activity score and with CPT1, SREBP, PPAR? and Col1A1 mRNA levels, and associated to portal fibrosis, in morbidly obese patients with NAFLD/NASH. GDF11-treated mice showed mildly exacerbated hepatic collagen deposition, accompanied by weight loss and without changes in liver steatosis or inflammation. GDF11 triggered ALK5-dependent SMAD2/…

Liver CirrhosisMaleAgingSettore MED/09 - Medicina Interna*liverLiver Cirrhosis ExperimentalFetgeWeight lossFibrosisfibrosis; growth differentiation factor 11; liver; NAFLD; NASHNon-alcoholic Fatty Liver DiseaseGrowth differentiation factor 11Fatty liverNASH*fibrosisMiddle AgedObesity MorbidGrowth Differentiation FactorsLiverBone Morphogenetic ProteinsDisease ProgressionFemalemedicine.symptomResearch PaperSignal TransductionAdultmedicine.medical_specialtygrowth differentiation factor 11Inflammationliverdigestive systemCell LineEnvellimentInternal medicineNAFLDmedicineHepatic Stellate CellsAnimalsHumansddc:612*growth differentiation factor 11business.industry*NAFLDfibrosisnutritional and metabolic diseasesCell Biologyliver NAFLD NASH fibrosis growth differentiation factor 11*NASHmedicine.diseaseFibrosisdigestive system diseasesMice Inbred C57BLEndocrinologyPortal fibrosisCase-Control StudiesGDF11Hepatic stellate cellSteatohepatitisHepatic fibrosisbusiness
researchProduct

Post-transplantation outcome in non-alcoholic steatohepatitis cirrhosis: Comparison with alcoholic cirrhosis.

2019

Abstract Introduction and objectives Non-alcoholic steatohepatitis (NASH) indication of liver transplant (LT) has increased recently, whereas alcoholic cirrhosis remains a major indication for LT. To characterize NASH-related cases and to compare the post-transplant outcome of these two conditions represents our major objective. Material and methods Patients undergoing LT for NASH between 1997 and 2016 were retrieved. Those transplanted between 1997 and 2006 were compared to an “age and LT date” matched group of patients transplanted for alcoholic cirrhosis (ratio 1:2). Baseline features and medium-term outcome measures were compared. Results Of 1986 LT performed between 1997 and 2016, 40 (…

Liver CirrhosisMaleAlcoholic liver diseaseCirrhosisHepatocellular carcinomamedicine.medical_treatmentSpecialties of internal medicineLiver transplantationGastroenterologyCohort Studies0302 clinical medicinePostoperative ComplicationsLiver Cirrhosis AlcoholicNon-alcoholic Fatty Liver DiseaseCause of DeathHyperuricemiaRenal InsufficiencyCardiovascular risk factorsIncidence (epidemiology)Liver NeoplasmsGeneral MedicineMiddle AgedSurvival RateTreatment OutcomeRC581-951Cardiovascular Diseases030220 oncology & carcinogenesisHepatocellular carcinomaHypertension030211 gastroenterology & hepatologyFemaleAlcoholAdultmedicine.medical_specialtyCarcinoma HepatocellularHyperuricemia03 medical and health sciencesYoung AdultInternal medicinemedicineDiabetes MellitusHumansObesityAgedDyslipidemiasRetrospective StudiesHepatologybusiness.industrynutritional and metabolic diseasesOverweightmedicine.diseasedigestive system diseasesLiver TransplantationSpainSteatohepatitisNeoplasm Recurrence LocalbusinessDyslipidemiaAnnals of hepatology
researchProduct

Characteristics and Changes over Time of Alcohol-Related Chronic Liver Diseases in Italy

2018

Introduction. To evaluate the characteristics of alcohol-related chronic liver disease (CLD) in Italy and their potential changes over time. Patients and Methods. Subjects with CLD were enrolled in two national surveys performed in 2001 and in 2014 in Italy. The two surveys prospectively recruited patients aged ≥ 18 years referring to more than 80 Italian liver units scattered all over the country using similar clinical approach, analytical methods, and threshold of risky alcohol intake definition (≥ 3 units/day in men and ≥ 2 units/day in women). Results. Out of 12,256 enrolled subjects, 2,717 (22.2%) reported a risky alcohol intake. Of them, anti-HCV positive was observed in 48.3% of subj…

Liver CirrhosisMaleCirrhosisChronic liver diseaseHealth Risk BehaviorsHealth Risk BehaviorLiver disease0302 clinical medicineStage (cooking)ChronicLiver DiseasesGastroenterologyGeneral MedicineHepatitis CHealth SurveyMiddle AgedAlcoholicHepatitis CAlcoholismItaly030220 oncology & carcinogenesis030211 gastroenterology & hepatologyFemaleSex ratioAdult; Aged; Alcohol Drinking; Alcoholism; Chronic Disease; Female; Health Risk Behaviors; Health Surveys; Hepatitis C Antibodies; Hepatitis C Chronic; Humans; Italy; Liver Cirrhosis; Liver Diseases Alcoholic; Male; Middle AgedResearch ArticleHumanAdultmedicine.medical_specialtyArticle SubjectAlcohol DrinkingLiver Cirrhosi03 medical and health sciencesInternal medicinemedicineHumanslcsh:RC799-869Liver Diseases AlcoholicAgedHepatologybusiness.industryHepatologyHepatitis C AntibodiesHepatitis C Chronicmedicine.diseaseHealth SurveysAgeingChronic Diseaselcsh:Diseases of the digestive system. GastroenterologybusinessHepatitis C Antibodie
researchProduct

The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2017 : a systematic analysis for the Global Bu…

2020

Background\ud \ud Cirrhosis and other chronic liver diseases (collectively referred to as cirrhosis in this paper) are a major cause of morbidity and mortality globally, although the burden and underlying causes differ across locations and demographic groups. We report on results from the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2017 on the burden of cirrhosis and its trends since 1990, by cause, sex, and age, for 195 countries and territories.\ud \ud \ud \ud Methods\ud \ud We used data from vital registrations, vital registration samples, and verbal autopsies to estimate mortality. We modelled prevalence of total, compensated, and decompensated cirrhosis on the bas…

Liver CirrhosisMaleCirrhosisCost-Benefit AnalysisHEPATITIS-BGlobal Burden of DiseaseLiver diseaseDisability Evaluation0302 clinical medicineBurden Global Mortality CirrhosisNon-alcoholic Fatty Liver DiseaseRisk FactorsFIBROSISEurope EasternPOPULATIONAged 80 and overeducation.field_of_studySingaporeMortality rate1. No povertyGastroenterologyHepatitis CHepatitis BMiddle AgedHepatitis BHepatitis C3. Good healthPREVALENCE030220 oncology & carcinogenesisAsia Central030211 gastroenterology & hepatologyEgyptFemaleQuality-Adjusted Life YearsViral hepatitisLife Sciences & BiomedicineAdultEUROPEPopulationGBD 2017 Cirrhosis CollaboratorsArticle03 medical and health sciencesLIVER-DISEASEmedicineHumanseducationLiver Diseases AlcoholicAfrica South of the SaharaAgedScience & TechnologyHepatologyGastroenterology & Hepatologybusiness.industryMORTALITYDISABILITYDECOMPENSATIONmedicine.diseaseYears of potential life lostEarly DiagnosisSocioeconomic Factors3121 General medicine internal medicine and other clinical medicineINJURIESHuman medicinebusinessDemographyRCLancet gastroenterology & hepatology
researchProduct

Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD : an individual patient data meta-analysis

2021

ObjectiveLiver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatty liver disease. The aims of this study were to evaluate the individual diagnostic performance of liver stiffness measurement by vibration controlled transient elastography (LSM-VCTE), Fibrosis-4 Index (FIB-4) and NAFLD (non-alcoholic fatty liver disease) Fibrosis Score (NFS) and to derive diagnostic strategies that could reduce the need for liver biopsies.DesignIndividual patient data meta-analysis of studies evaluating LSM-VCTE against liver histology was conducted. FIB-4 and NFS were computed where possible. Sensitivity, specificity and area under the receiver operating curve (AUROC) were c…

Liver CirrhosisMaleCirrhosisLIVER STIFFNESS MEASUREMENTBiopsy[SDV]Life Sciences [q-bio]biostatisticsGastroenterologyDISEASEbiostatistics; clinical decision making; fatty liver; hepatic fibrosis0302 clinical medicineNon-alcoholic Fatty Liver DiseaseFibrosishepatic fibrosis2. Zero hunger0303 health sciencesmedicine.diagnostic_testNONALCOHOLIC STEATOHEPATITISTRANSIENT ELASTOGRAPHYFatty liverGastroenterologyCHRONIC HEPATITISMiddle Aged3. Good healthSettore AGR/03 - Arboricoltura Generale E Coltivazioni ArboreeLiverLiver biopsyBIOPSYElasticity Imaging TechniquesFemale030211 gastroenterology & hepatologyMedian bodymedicine.medical_specialtyCONTROLLED ATTENUATION PARAMETER610 Medicine & healthclinical decision making03 medical and health sciencesInternal medicineSCOREmedicineHumansbiostatistics clinical decision making fatty liver hepatic fibrosisfatty liver030304 developmental biologyReceiver operating characteristicbusiness.industrymedicine.diseaseFibrosisDiabetes Mellitus Type 2XL PROBEbusinessHepatic fibrosisTransient elastographyBiomarkersPROSPECTIVE DERIVATIONGut : the journal of the British Society for Gastroenterology
researchProduct

Genetic susceptibility of increased intestinal permeability is associated with progressive liver disease and diabetes in patients with non-alcoholic …

2020

Abstract Background and aim Increased intestinal permeability plays a key role in the pathogenesis of fat deposition in the liver. The aim of our study was to assess whether a single nucleotide polymorphism of protein tyrosine phosphatase non-receptor type 2 (PTPN2) (rs2542151 T→G), involved in intestinal permeability, may be associated with non-alcoholic fatty liver disease (NAFLD) and type 2 diabetes mellitus (T2DM). Methods and results We recruited a prospective cohort of NAFLD subjects and matched controls. Clinical data, PTPN2 genotype and laboratory data were collected for each patient. Results were stratified according to liver histology and diabetes. We enrolled 566 cases and 377 co…

Liver CirrhosisMaleEndocrinology Diabetes and MetabolismMedicine (miscellaneous)030204 cardiovascular system & hematologySeverity of Illness IndexGastroenterologyLiver disease0302 clinical medicineNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver diseasePrevalenceProspective StudiesProtein Tyrosine Phosphatase Non-Receptor Type 2Nutrition and Dieteticsmedicine.diagnostic_testFatty liverMiddle AgedPhenotypeItalyLiver biopsyFemaleCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtySettore MED/12 - GASTROENTEROLOGIA030209 endocrinology & metabolismIntestinal permeabilityPolymorphism Single NucleotideRisk AssessmentPermeability03 medical and health sciencesInternal medicineDiabetes mellitusmedicineGenetic susceptibilityHumansNonalcoholic fatty liver diseaseGenetic Predisposition to DiseaseGenetic Association Studiesbusiness.industryType 2 Diabetes Mellitusmedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 2Intestinal AbsorptionCase-Control StudiesSteatosisSteatohepatitisbusiness
researchProduct

Ovarian senescence increases liver fibrosis in humans and zebrafish with steatosis

2015

ABSTRACT Contrasting data exist on the effect of gender and menopause on the susceptibility, development and liver damage progression in non-alcoholic fatty liver disease (NAFLD). Our aim was to assess whether menopause is associated with the severity of liver fibrosis in individuals with NAFLD and to explore the issue of ovarian senescence in experimental liver steatosis in zebrafish. In 244 females and age-matched males with biopsy-proven NAFLD, we assessed anthropometric, biochemical and metabolic features, including menopausal status (self-reported); liver biopsy was scored according to ‘The Pathology Committee of the NASH Clinical Research Network’. Young and old male and female zebraf…

Liver CirrhosisMaleFibrosiBiopsyPhysiologylcsh:MedicineMedicine (miscellaneous)Body Mass IndexCohort StudiesImmunology and Microbiology (miscellaneous)FibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsOdds RatioZebrafishCellular Senescencemedicine.diagnostic_testAnthropometryFatty liverMiddle AgedOvarian senescenceMenopauseLiver biopsyModels AnimalDisease ProgressionFemaleMenopauselcsh:RB1-214Research ArticleSenescenceAdultmedicine.medical_specialtyFibrosis Menopause Non-alcoholic fatty liver disease Ovarian senescence ZebrafishNeuroscience (miscellaneous)Fibrosis; Menopause; Non-alcoholic fatty liver disease; Ovarian senescence; Zebrafish; Biochemistry Genetics and Molecular Biology (all); Medicine (miscellaneous); Immunology and Microbiology (miscellaneous); Neuroscience (miscellaneous)BiologyReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyInternal medicinemedicinelcsh:PathologyAnimalsHumansAgedBiochemistry Genetics and Molecular Biology (all)lcsh:RSettore MED/09 - MEDICINA INTERNAOvaryOdds ratiomedicine.diseaseFibrosisEndocrinologySteatosisBody mass indexDisease Models & Mechanisms
researchProduct

Metabolic syndrome and severity of fibrosis in nonalcoholic fatty liver disease: An age-dependent risk profiling study

2017

Background & Aims: Metabolic syndrome (MS) and its individual components are associated with the severity and progression of nonalcoholic fatty liver disease (NAFLD). We sought to evaluate the relationship between MS components and the risk of severe hepatic fibrosis in NAFLD patients discriminated by age. Methods: We considered 863 consecutive patients with biopsy-proven NAFLD, who had been fully evaluated for components of MS. Results: Multivariate logistic regression analysis showed that F3-F4 was associated with visceral obesity, IFG/diabetes, and low high-density lipoprotein (HDL) cholesterol, but not triglycerides >150 or arterial hypertension. A significant interaction was found betw…

Liver CirrhosisMaleGastroenterologyBody Mass Index0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseRisk FactorsNonalcoholic fatty liver disease10. No inequalityDiabetesAge FactorsMiddle AgedMetabolic syndrome3. Good healthItalyLiver030220 oncology & carcinogenesisObesity Abdominal030211 gastroenterology & hepatologyFemaleWaist CircumferenceLipoproteins HDLAdultmedicine.medical_specialtyDiabetes Complications03 medical and health sciencesDiabetes mellitusInternal medicinemedicineHumansNonalcoholic fatty liver diseaseObesityAgedDiabetes; Metabolic syndrome; Nonalcoholic fatty liver disease; Obesity; HepatologyHepatologybusiness.industrynutritional and metabolic diseasesHepatologymedicine.diseaseObesityMiddle ageCross-Sectional StudiesLogistic ModelsdiabeteMultivariate AnalysisMetabolic syndromeInsulin ResistanceHepatic fibrosisbusiness
researchProduct

PNPLA3 rs738409 I748M is associated with steatohepatitis in 434 non-obese subjects with hepatitis C

2015

Summary Background The PNPLA3/Adiponutrin rs738409 C/G single nucleotide polymorphism is associated with the severity of steatosis, steatohepatitis and fibrosis in patients with non-alcoholic fatty liver disease, as well as the severity of steatosis and fibrosis in patients with chronic hepatitis C (CHC). Aim To test in genotype 1(G1)-CHC patients, the putative association between the PNPLA3 variant and histological features of steatohepatitis, as well as their impact on the severity of fibrosis. Methods Four hundred and thirty-four consecutively biopsied Caucasian G1-CHC patients were genotyped for PNPLA3 rs738409, its effect evaluated by using an additive model. Histological features of s…

Liver CirrhosisMaleHepacivirusGastroenterologyCohort StudiesNon-alcoholic Fatty Liver DiseaseFibrosisGenotypePharmacology (medical)ChronicMembrane ProteinSettore MED/12 - Gastroenterologiaeducation.field_of_studyMedicine (all)Fatty liverGastroenterologySingle NucleotideHepatitis CMiddle AgedHepatitis CFemaleHumanAdultmedicine.medical_specialtyLogistic ModelGenotypeLiver CirrhosiEuropean Continental Ancestry GroupSingle-nucleotide polymorphismSettore MED/08 - Anatomia PatologicaPolymorphism Single NucleotideWhite PeopleInternal medicinemedicineHumansAdiponutrinObesityPolymorphismeducationAdult; Cohort Studies; European Continental Ancestry Group; Fatty Liver; Female; Genotype; Hepacivirus; Hepatitis C Chronic; Humans; Lipase; Liver Cirrhosis; Logistic Models; Male; Membrane Proteins; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Polymorphism Single Nucleotide; Pharmacology (medical); Medicine (all)HepaciviruHepatologybusiness.industryMembrane ProteinsLipaseHepatitis C Chronicmedicine.diseaseFatty LiverLogistic ModelsCohort StudieSteatosisSteatohepatitisbusinessAlimentary Pharmacology & Therapeutics
researchProduct

The Presence of White Matter Lesions Is Associated With the Fibrosis Severity of Nonalcoholic Fatty Liver Disease

2016

Abstract We tested whether nonalcoholic fatty liver disease (NAFLD) and/or its histological severity are associated with vascular white matter lesions (WML) in patients with biopsy-proven NAFLD and in non-NAFLD controls. Data were recorded in 79 consecutive biopsy-proven NAFLD, and in 82 controls with normal ALT and no history of chronic liver diseases, without ultrasonographic evidence of steatosis and liver stiffness value  45 years (OR 3.09, 95% CI: 1.06–9.06, P = 0.03; and OR 11.1, 95% CI: 1.14–108.7, P = 0.03), and F2–F4 fibrosis (OR 3.36, 95% CI: 1.29–8.73, P = 0.01; and OR 5.34, 95% CI: 1.40–20.3, P = 0.01) were independently associated with WML (mostly of mild grade) by multivariate…

Liver CirrhosisMalePathologyBiopsySeverity of Illness IndexGastroenterology0302 clinical medicineRisk FactorsNon-alcoholic Fatty Liver DiseaseFibrosisNonalcoholic fatty liver diseaseUltrasonography4500Brain DiseasesSettore MED/12 - Gastroenterologiamedicine.diagnostic_testMedicine (all)Brain DiseaseGeneral MedicineMiddle AgedMagnetic Resonance ImagingWhite MatterFrontal Lobemedicine.anatomical_structureLiverFemale030211 gastroenterology & hepatologyNAFLD liver biopsy fibrosis white matter lesionsResearch ArticleHumanmedicine.medical_specialtyLiver CirrhosiObservational StudySettore MED/08 - Anatomia PatologicaDiagnosis DifferentialWhite matter03 medical and health sciencesInternal medicineBiopsySeverity of illnessmedicineHumansbusiness.industryRisk Factornutritional and metabolic diseasesmedicine.diseasedigestive system diseasesHyperintensityDifferential diagnosisSteatosisSettore MED/36 - Diagnostica Per Immagini E Radioterapiabusiness030217 neurology & neurosurgeryMedicine
researchProduct